Table 1.
Characteristics of the whole study population
| Variables | Overall (n = 411) | Resectable group (n = 254) | Unresectable group (n = 157) |
|---|---|---|---|
| Age (years)1 | 60 (26–82) | 61 (26–82) | 58 (28–81) |
| Gender | |||
| Male | 263 | 159 | 104 |
| Female | 147 | 94 | 53 |
| BMI2 | 22.3 (17.2–28.6) | 22.0 (17.2–28.6) | 23.0 (17.6–28.6) |
| ASA score | |||
| 1 | 12 (2.9%) | 6 (2.4%) | 6 (3.8%) |
| 2 | 224 (54.5%) | 140 (5.5%) | 84 (53.5%) |
| 3 | 175 (42.6%) | 108 (42.5%) | 67 (42.7%) |
| Total bilirubin (μmol/L)2 | 224.74 ± 162.22 | 206.72 ± 172.04 | 253.90 ± 140.60 |
| CA-199 (U/mL)2 | 450.19 ± 369.53 | 414.38 ± 369.55 | 419.30 ± 363.23 |
| Albumin (g/L)2 | 37.05 ± 5.23 | 36.94 ± 5.18 | 37.19 ± 5.39 |
| Preoperative neutrophil count (× 109/L)2 | 4.77 ± 2.52 | 4.61 ± 2.41 | 5.03 ± 2.68 |
| Preoperative monocyte count (× 109/L)2 | 0.52 ± 0.19 | 0.52 ± 0.19 | 0.52 ± 0.19 |
| Preoperative lymphocyte count (× 109/L)2 | 2.05 ± 0.79 | 2.13 ± 0.81 | 1.91 ± 0.75 |
| Postoperative neutrophil count (× 109/L)2 | 4.40 ± 1.37 | 4.23 ± 1.22 | 4.68 ± 1.55 |
| Postoperative monocyte count (× 109/L)2 | 0.51 ± 0.17 | 0.50 ± 0.17 | 0.52 ± 0.17 |
| Postoperative lymphocyte count (× 109/L)2 | 2.29 ± 0.88 | 2.27 ± 0.76 | 2.34 ± 1.04 |
| Total lymph nodes evaluated1 | 4 (1–12) | 3 (1–9) | 5 (1–12) |
| Positive lymph node number1 | 2 (0–10) | 0 (0–7) | 4 (1–10) |
| Operative time (min)1 | 240.00 (80–720) | 250 (110–720) | 180 (80–500) |
| Blood loss (mL)2 | 500 (50–2000) | 600 (100–2000) | 300 (50–1000) |
| Blood transfusion | 123 (30.0%) | 84 (33.0%) | 39 (24.8%) |
| Any complication | 184 (44.8%) | 141 (55.5%) | 43 (27.3%) |
| Major complication (Clavien-Dindo II-IV) | 117 (28.5%) | 93 (36.6%) | 24 (15.3%) |
| Hospital stay (days)1 | 18 (5–113) | 18 (5–113) | 17 (5–43) |
| Preoperative hospital stay (days)1 | 7 (2–44) | 7 (2–44) | 7 (3–33) |
| Postoperative adjuvant therapy | 154 (37.3%) | 117 (46.1%) | 37 (23.6%) |
1Parameters are presented as median and range
2Parameters are presented as mean ± SD